Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms

PLoS Computational Biology

Volumn 10, Issue 2, 2014, Pages

  Bilsland, Alan E ^a   Stevenson, Katrina ^a   Liu, Yu ^a   Hoare, Stacey ^a   Cairney, Claire J ^a   Roffey, Jon ^b   Keith, W Nicol ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELLS; COMPLEX NETWORKS; CONTROLLED DRUG DELIVERY; DISEASES; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

CANCER CELLS; CELL-BASED; EXPRESSION MECHANISM; IN CONTEXTS; INHIBITOR EFFECTS; SCREENING ANALYSIS; TELOMERASE; TELOMERASE EXPRESSION; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTIONAL REGULATORY NETWORKS;

TRANSCRIPTION;

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 6 BROMOINDIRUBIN 3' OXIME; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYC PROTEIN; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ETS2 PROTEIN, HUMAN; FR 180204; GLYCOGEN SYNTHASE KINASE 3; INDOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; SULFONAMIDE; TELOMERASE; TERT PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS 2;

AR GENE; ARTICLE; BOOLEAN THRESHOLD NETWORK MODEL; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; GENE INTERACTION; GENE LOSS; GENE REGULATORY NETWORK; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; JUN GENE; MATHEMATICAL MODEL; MXD1 GENE; NOISE; OVARY ADENOCARCINOMA; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SP3 GENE; TERT GENE; TP53 GENE; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; MATHEMATICAL PHENOMENA; METABOLISM; NEOPLASMS; ONCOGENE MYC; OVARIAN NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; ENZYME INHIBITORS; FEMALE; GENE REGULATORY NETWORKS; GENES, MYC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; MATHEMATICAL CONCEPTS; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEIN C-ETS-2; PYRAZOLES; PYRIDAZINES; SIGNAL TRANSDUCTION; SULFONAMIDES; TELOMERASE; TRANSFECTION;

EID: 84895749343     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003448     Document Type: Article

References (106)

1. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Daniel M, Peek GW, Tollefsbol TO, (2012) Regulation of the human catalytic subunit of telomerase (hTERT). Gene 498: 135-146.
3. Tang B, Hsu PY, Huang TH, Jin VX, (2012) Cancer omics: From regulatory networks to clinical outcomes. Cancer Lett 340 (2):: 277-83.
4. Bilsland AE, Hoare S, Stevenson K, Plumb J, Gomez-Roman N, et al. (2009) Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS One 4: e6459.
5. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, et al. (2009) A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 28: 3765-3774.
6. Yao Y, Bellon M, Shelton SN, Nicot C, (2012) Tumor suppressors p53, p63TAalpha, p63TAy, p73alpha, and p73beta use distinct pathways to repress telomerase expression. J Biol Chem 287: 20737-20747.
7. Won J, Yim J, Kim TK, (2002) Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells. Faseb J 16: 1943-1945.
8. Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, et al. (2010) Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 103: 1255-1262.
9. Nelson DE, See V, Nelson G, White MR, (2004) Oscillations in transcription factor dynamics: a new way to control gene expression. Biochem Soc Trans 32: 1090-1092.
10. Bilsland AE, Revie J, Keith W, (2013) MicroRNA and Senescence: The Senectome, Integration and Distributed Control. Crit Rev Oncog 18: 373-390.
11. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273.
12. Wrobel G, Chalmel F, Primig M, (2005) goCluster integrates statistical analysis and functional interpretation of microarray expression data. Bioinformatics 21: 3575-3577.
13. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
14. Geard N, Willadsen K (2009) Dynamical approaches to modeling developmental gene regulatory networks. Birth Defects Res C Embryo Today. pp. 131-142.
15. von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, et al. (2009) Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol 11: 1458-1464.
16. Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, et al. (2011) Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. Cell Signal 23: 407-416.
17. Benson N, Matsuura T, Smirnov S, Demin O, Jones HM, et al. (2013) Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3: 20120071.
18. Grefenstette J, Kim S, Kauffman S, (2006) An analysis of the class of gene regulatory functions implied by a biochemical model. Biosystems 84: 81-90.
19. Kauffman S, Peterson C, Samuelsson B, Troein C, (2003) Random Boolean network models and the yeast transcriptional network. Proc Natl Acad Sci U S A 100: 14796-14799.
20. Akman OE, Watterson S, Parton A, Binns N, Millar AJ, et al. (2012) Digital clocks: simple Boolean models can quantitatively describe circadian systems. J R Soc Interface 9 (74):: 2365-82.
21. Lee WB, Huang JY, (2009) Robustness and topology of the yeast cell cycle Boolean network. FEBS Lett 583: 927-932.
22. Schlatter R, Schmich K, Avalos Vizcarra I, Scheurich P, Sauter T, et al. (2009) ON/OFF and beyond-a boolean model of apoptosis. PLoS Comput Biol 5: e1000595.
23. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
24. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
25. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110: 6021-6026.
26. Bilsland AE, Fletcher-Monaghan A, Keith WN, (2005) Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia 7: 1020-1029.
27. Takakura M, Kyo S, Inoue M, Wright WE, Shay JW, (2005) Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 25: 8037-8043.
28. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH, (2005) Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 65: 6516-6520.
29. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN, (2006) Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25: 61-69.
30. Anest V, Cogswell PC, Baldwin AS Jr, (2004) IkappaB kinase alpha and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of IkappaBalpha degradation. J Biol Chem 279: 31183-31189.
31. Angel P, Hattori K, Smeal T, Karin M, (1988) The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55: 875-885.
32. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70: 1377-1388.
33. Chen LI, Nishinaka T, Kwan K, Kitabayashi I, Yokoyama K, et al. (1994) The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator. Mol Cell Biol 14: 4380-4389.
34. Crowe DL, Nguyen DC, Tsang KJ, Kyo S, (2001) E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 29: 2789-2794.
35. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, et al. (2006) Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 66: 11897-11906.
36. Duan R, Porter W, Safe S, (1998) Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139: 1981-1990.
37. Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, et al. (2010) Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32: 605-615.
38. Gizard F, Heywood EB, Findeisen HM, Zhao Y, Jones KL, et al. (2011) Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. Arterioscler Thromb Vasc Biol 31: 245-252.
39. Ho JS, Ma W, Mao DY, Benchimol S, (2005) p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 25: 7423-7431.
40. Hossain S, Takatori A, Nakamura Y, Suenaga Y, Kamijo T, et al. (2012) NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo. Cancer Res 72: 4587-4596.
41. Hsu SP, Lee WS, (2011) Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells. Mol Endocrinol 25: 421-432.
42. Jiang K, Hein N, Eckert K, Luscher-Firzlaff J, Luscher B, (2008) Regulation of the MAD1 promoter by G-CSF. Nucleic Acids Res 36: 1517-1531.
43. Johnson DG, Ohtani K, Nevins JR, (1994) Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8: 1514-1525.
44. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, et al. (2000) Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 6: 1239-1247.
45. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR, (1992) Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res 20: 4083-4087.
46. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, et al. (2000) Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28: 669-677.
47. Mac SM, D'Cunha CA, Farnham PJ, (2000) Direct recruitment of N-myc to target gene promoters. Mol Carcinog 29: 76-86.
48. Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, et al. (2008) Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J 22: 1258-1267.
49. Nicolas M, Noe V, Ciudad CJ, (2003) Transcriptional regulation of the human Sp1 gene promoter by the specificity protein (Sp) family members nuclear factor Y (NF-Y) and E2F. Biochem J 371: 265-275.
50. Oh S, Song YH, Yim J, Kim TK, (2000) Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 19: 1485-1490.
51. Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, et al. (2003) Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 100: 7331-7336.
52. Ookawa K, Tsuchida S, Kohno T, Yokota J, (2001) Alterations in expression of E2F-1 and E2F-responsive genes by RB, p53 and p21(Sdi1/WAF1/Cip1) expression. FEBS Lett 500: 25-30.
53. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, et al. (2005) Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24: 6773-6784.
54. Sengupta T, Abraham G, Xu Y, Clurman BE, Minella AC, (2011) Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis. Mol Cell Biol 31: 3885-3895.
55. Tapias A, Ciudad CJ, Noe V, (2008) Transcriptional regulation of the 5′-flanking region of the human transcription factor Sp3 gene by NF-1, c-Myb, B-Myb, AP-1 and E2F. Biochim Biophys Acta 1779: 318-329.
56. Tapias A, Ciudad CJ, Roninson IB, Noe V, (2008) Regulation of Sp1 by cell cycle related proteins. Cell Cycle 7: 2856-2867.
57. Thalmeier K, Synovzik H, Mertz R, Winnacker EL, Lipp M, (1989) Nuclear factor E2F mediates basic transcription and trans-activation by E1a of the human MYC promoter. Genes Dev 3: 527-536.
58. Wang Q, Bai Z, Li X, Hou L, Zhang B, (2004) The evidences of human orphan receptor COUP-TFII inhibiting telomerase activity through decreasing hTERT transcription. Cancer Lett 214: 81-90.
59. Wooten-Blanks LG, Song P, Senkal CE, Ogretmen B, (2007) Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J 21: 3386-3397.
60. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, et al. (1999) Direct activation of TERT transcription by c-MYC. Nat Genet 21: 220-224.
61. Xing Y, Zhou F, Wang J, (2013) Subset of genes targeted by transcription factor NF-kappaB in TNFalpha-stimulated human HeLa cells. Funct Integr Genomics 13: 143-154.
62. Yang E, Lerner L, Besser D, Darnell JE Jr, (2003) Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 278: 15794-15799.
63. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 103: 17834-17839.
64. Chen X, Qin J, Cheng CM, Tsai MJ, Tsai SY, (2012) COUP-TFII is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol 26: 1268-1277.
65. Cho K, Shin HW, Kim YI, Cho CH, Chun YS, et al. (2013) Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function. Free Radic Biol Med 60: 201-210.
66. Choi M, Lee H, Rho HM, (2002) E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. IUBMB Life 53: 309-317.
67. Kim TH, Lee SY, Rho JH, Jeong NY, Soung YH, et al. (2009) Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. Mol Cancer Res 7: 1645-1654.
68. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, et al. (2011) Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2: 1203-1217.
69. Niu G, Wright KL, Ma Y, Wright GM, Huang M, et al. (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25: 7432-7440.
70. Schonthal A, Buscher M, Angel P, Rahmsdorf HJ, Ponta H, et al. (1989) The Fos and Jun/AP-1 proteins are involved in the downregulation of Fos transcription. Oncogene 4: 629-636.
71. Sivak LE, Tai KF, Smith RS, Dillon PA, Brodeur GM, et al. (1997) Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 15: 1937-1946.
72. Yuan H, Pan Y, Young CY, (2004) Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 213: 155-163.
73. Willadsen K, Wiles J, (2007) Robustness and state-space structure of Boolean gene regulatory models. J Theor Biol 249: 749-765.
74. Cho J, Rameshwar P, Sadoshima J, (2009) Distinct roles of glycogen synthase kinase (GSK)-3alpha and GSK-3beta in mediating cardiomyocyte differentiation in murine bone marrow-derived mesenchymal stem cells. J Biol Chem 284: 36647-36658.
75. Mangan S, Alon U, (2003) Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci U S A 100: 11980-11985.
76. White DR, Borgatti SP, (1994) Betweenness centrality measures for directed graphs. Social Networks 16: 335-346.
77. Freeman LC, Borgatti SP, White DR, (1991) Centrality in valued graphs: a measure of betweenness based on network flow. Social Networks 13: 141-154.
78. Huang S, Ernberg I, Kauffman S, (2009) Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 20: 869-876.
79. Lafferty-Whyte K, Bilsland A, Hoare SF, Burns S, Zaffaroni N, et al. (2010) TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia 12: 405-414.
80. Lin SY, Elledge SJ, (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113: 881-889.
81. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, et al. (2001) Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 98: 3826-3831.
82. Maki-Marttunen T, Kesseli J, Nykter M, (2013) Balance between noise and information flow maximizes set complexity of network dynamics. PLoS One 8: e56523.
83. Torres-Sosa C, Huang S, Aldana M, (2012) Criticality is an emergent property of genetic networks that exhibit evolvability. PLoS Comput Biol 8: e1002669.
84. Arkus N, (2005) A mathematical model of cellular apoptosis and senescence through the dynamics of telomere loss. J Theor Biol 235: 13-32.
85. Lawless C, Jurk D, Gillespie CS, Shanley D, Saretzki G, et al. (2012) A stochastic step model of replicative senescence explains ROS production rate in ageing cell populations. PLoS One 7: e32117.
86. De Cian A, Lacroix L, Douarre C, Temime-Smaali N, Trentesaux C, et al. (2008) Targeting telomeres and telomerase. Biochimie 90: 131-155.
87. Billingsley DJ, Bonass WA, Crampton N, Kirkham J, Thomson NH, (2012) Single-molecule studies of DNA transcription using atomic force microscopy. Phys Biol 9: 021001.
88. Graudenzi A, Serra R, Villani M, Damiani C, Colacci A, et al. (2011) Dynamical properties of a boolean model of gene regulatory network with memory. J Comput Biol 18: 1291-1303.
89. Wilds R, Kauffman SA, Glass L, (2008) Evolution of complex dynamics. Chaos 18: 033109.
90. Agrawal A, Dang S, Gabrani R, (2012) Recent patents on anti-telomerase cancer therapy. Recent Pat Anticancer Drug Discov 7: 102-117.
91. Keith WN, Bilsland AE (2008) Targeting telomerase: Therapeutic options for cancer treatment. Telomeres and Telomerase in Ageing, Disease, and Cancer: Springer-Verlag Berlin. pp. 247-283.
92. Lafferty-Whyte K, Bilsland A, Cairney CJ, Hanley L, Jamieson NB, et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics 11: 532.
93. Bilsland AE, Stevenson K, Atkinson S, Kolch W, Keith WN, (2006) Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. Cancer Res 66: 1363-1370.
94. Zhao J, Bilsland A, Jackson K, Keith WN, (2005) MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer 5: 6.
95. Bell LA, O'Prey J, Ryan KM, (2006) DNA-binding independent cell death from a minimal proapoptotic region of E2F-1. Oncogene 25: 5656-5663.
96. Ryan KM, Ernst MK, Rice NR, Vousden KH, (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404: 892-897.
97. Black EJ, Walker M, Clark W, MacLaren A, Gillespie DA, (2002) Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogene 21: 6540-6548.
98. Crouch DH, Fisher F, La Rocca SA, Goding CR, Gillespie DA, (2005) Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain. Nucleic Acids Res 33: 5235-5242.
99. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY, (2002) Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 21: 5069-5080.
100. Machado D, Costa RS, Rocha M, Ferreira EC, Tidor B, et al. (2011) Modeling formalisms in Systems Biology. AMB Express 1: 45.
101. Xiao Y, (2009) A tutorial on analysis and simulation of boolean gene regulatory network models. Curr Genomics 10: 511-525.
102. Wuensche A, (1998) Genomic regulation modeled as a network with basins of attraction. Pac Symp Biocomput pp. 89-102.
103. Batagelj V, Mrvar A, (1998) Pajek: a program for large network analysis. Connections 21: 47-58.
104. Borgatti SP, Everett MG, Freeman LC (2002) Ucinet for Windows: software for social network analysis. Harvard, MA: Analytic Technologies.
105. Kohl M, Wiese S, Warscheid B, (2011) Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol 696: 291-303.
106. Jiang C, Xuan Z, Zhao F, Zhang MQ, (2007) TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res 35: D137-140.